Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

GSK earns FDA approval for Jideytro — Jul 23, 2026GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.